Centersquare Investment Management LLC Has $1.59 Million Holdings in COPT Defense Properties $CDP

Centersquare Investment Management LLC lessened its stake in COPT Defense Properties (NYSE:CDP) by 20.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 57,000 shares of the company’s stock after selling 15,000 shares during the period. Centersquare Investment Management LLC’s holdings in COPT Defense Properties were worth $1,585,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of CDP. Royal Bank of Canada raised its position in COPT Defense Properties by 12.1% in the 1st quarter. Royal Bank of Canada now owns 104,602 shares of the company’s stock worth $2,853,000 after purchasing an additional 11,316 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in COPT Defense Properties by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 67,030 shares of the company’s stock worth $1,828,000 after purchasing an additional 2,931 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in COPT Defense Properties by 5.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 834,042 shares of the company’s stock worth $22,744,000 after purchasing an additional 39,683 shares during the last quarter. Jane Street Group LLC raised its position in COPT Defense Properties by 152.4% in the 1st quarter. Jane Street Group LLC now owns 214,122 shares of the company’s stock worth $5,839,000 after purchasing an additional 129,303 shares during the last quarter. Finally, Invesco Ltd. raised its position in COPT Defense Properties by 11.8% in the 2nd quarter. Invesco Ltd. now owns 758,513 shares of the company’s stock worth $20,920,000 after purchasing an additional 80,153 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on CDP shares. Weiss Ratings upgraded shares of COPT Defense Properties from a “buy (b-)” rating to a “buy (b)” rating in a research report on Tuesday, April 21st. Wells Fargo & Company boosted their price objective on shares of COPT Defense Properties from $35.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. JPMorgan Chase & Co. boosted their price objective on shares of COPT Defense Properties from $33.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, May 15th. Cantor Fitzgerald restated an “overweight” rating and issued a $37.00 price objective on shares of COPT Defense Properties in a research report on Wednesday, April 29th. Finally, Truist Financial boosted their price objective on shares of COPT Defense Properties from $33.00 to $34.00 and gave the stock a “hold” rating in a research report on Monday. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, COPT Defense Properties presently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Insider Activity at COPT Defense Properties

In other COPT Defense Properties news, Director Robert L. Denton sold 3,922 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $32.38, for a total transaction of $126,994.36. Following the completion of the sale, the director owned 3,803 shares in the company, valued at approximately $123,141.14. The trade was a 50.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.66% of the company’s stock.

COPT Defense Properties Stock Performance

Shares of COPT Defense Properties stock opened at $34.32 on Friday. The firm has a fifty day moving average of $32.03 and a two-hundred day moving average of $31.04. The stock has a market capitalization of $3.89 billion, a price-to-earnings ratio of 24.87 and a beta of 0.79. COPT Defense Properties has a 52 week low of $26.91 and a 52 week high of $34.78. The company has a debt-to-equity ratio of 1.63, a quick ratio of 2.85 and a current ratio of 2.85.

COPT Defense Properties (NYSE:CDP) last issued its earnings results on Monday, April 27th. The company reported $0.34 EPS for the quarter, missing the consensus estimate of $0.68 by ($0.34). The business had revenue of $200.64 million for the quarter, compared to the consensus estimate of $185.10 million. COPT Defense Properties had a net margin of 20.10% and a return on equity of 10.02%. The business’s revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.65 EPS. COPT Defense Properties has set its FY 2026 guidance at 2.730-2.790 EPS and its Q2 2026 guidance at 0.680-0.700 EPS. As a group, equities research analysts predict that COPT Defense Properties will post 2.78 EPS for the current year.

COPT Defense Properties Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.32 per share. The ex-dividend date is Tuesday, June 30th. This represents a $1.28 annualized dividend and a dividend yield of 3.7%. COPT Defense Properties’s payout ratio is presently 92.75%.

COPT Defense Properties Profile

COPT Defense Properties (NYSE: CDP) is a real estate investment trust organized to own, lease and manage healthcare and life science facilities serving the United States federal government, with a particular focus on Department of Defense and Veterans Affairs tenants. The company was formed in 2016 through a spin-off from Corporate Office Properties Trust, enabling it to concentrate exclusively on medical office buildings and specialized research facilities situated on or near military and federal research campuses.

The company’s portfolio comprises purpose-built, Class A medical office and outpatient specialty clinics, as well as life science laboratories.